275 related articles for article (PubMed ID: 16291763)
1. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys.
Arévalo-Herrera M; Castellanos A; Yazdani SS; Shakri AR; Chitnis CE; Dominik R; Herrera S
Am J Trop Med Hyg; 2005 Nov; 73(5 Suppl):25-31. PubMed ID: 16291763
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein.
Yazdani SS; Shakri AR; Mukherjee P; Baniwal SK; Chitnis CE
Vaccine; 2004 Sep; 22(27-28):3727-37. PubMed ID: 15315853
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
[TBL] [Abstract][Full Text] [Related]
4. Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques.
Moreno A; Caro-Aguilar I; Yazdani SS; Shakri AR; Lapp S; Strobert E; McClure H; Chitnis CE; Galinski MR
Vaccine; 2008 Aug; 26(34):4338-44. PubMed ID: 18573299
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection.
Giraldo MA; Arevalo-Pinzon G; Rojas-Caraballo J; Mongui A; Rodriguez R; Patarroyo MA
Vaccine; 2009 Dec; 28(1):7-13. PubMed ID: 19782110
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody.
Rawlinson TA; Barber NM; Mohring F; Cho JS; Kosaisavee V; Gérard SF; Alanine DGW; Labbé GM; Elias SC; Silk SE; Quinkert D; Jin J; Marshall JM; Payne RO; Minassian AM; Russell B; Rénia L; Nosten FH; Moon RW; Higgins MK; Draper SJ
Nat Microbiol; 2019 Sep; 4(9):1497-1507. PubMed ID: 31133755
[TBL] [Abstract][Full Text] [Related]
8. Targeting a Reticulocyte Binding Protein and Duffy Binding Protein to Inhibit Reticulocyte Invasion by Plasmodium vivax.
Gupta S; Singh S; Popovici J; Roesch C; Shakri AR; Guillotte-Blisnick M; Huon C; Menard D; Chitnis CE
Sci Rep; 2018 Jul; 8(1):10511. PubMed ID: 30002416
[TBL] [Abstract][Full Text] [Related]
9. Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants.
Carvalho LJ; Alves FA; Bianco C; Oliveira SG; Zanini GM; Soe S; Druilhe P; Theisen M; Muniz JA; Daniel-Ribeiro CT
Clin Diagn Lab Immunol; 2005 Feb; 12(2):242-8. PubMed ID: 15699417
[TBL] [Abstract][Full Text] [Related]
10. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein.
Grimberg BT; Udomsangpetch R; Xainli J; McHenry A; Panichakul T; Sattabongkot J; Cui L; Bockarie M; Chitnis C; Adams J; Zimmerman PA; King CL
PLoS Med; 2007 Dec; 4(12):e337. PubMed ID: 18092885
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Plasmodium vivax Duffy-binding protein.
Chitnis CE; Sharma A
Trends Parasitol; 2008 Jan; 24(1):29-34. PubMed ID: 18023618
[TBL] [Abstract][Full Text] [Related]
12. Production of recombinant PvDBPII, receptor binding domain of Plasmodium vivax Duffy binding protein, and evaluation of immunogenicity to identify an adjuvant formulation for vaccine development.
Bhardwaj R; Shakri AR; Hans D; Gupta P; Fernandez-Becerra C; Del Portillo HA; Pandey G; Chitnis CE
Protein Expr Purif; 2017 Aug; 136():52-57. PubMed ID: 26578115
[TBL] [Abstract][Full Text] [Related]
13. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein.
Arévalo-Herrera M; Solarte Y; Yasnot MF; Castellanos A; Rincón A; Saul A; Mu J; Long C; Miller L; Herrera S
Am J Trop Med Hyg; 2005 Nov; 73(5 Suppl):32-7. PubMed ID: 16291764
[TBL] [Abstract][Full Text] [Related]
14. Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.
Bouillet LÉ; Dias MO; Dorigo NA; Moura AD; Russell B; Nosten F; Renia L; Braga EM; Gazzinelli RT; Rodrigues MM; Soares IS; Bruna-Romero O
Infect Immun; 2011 Sep; 79(9):3642-52. PubMed ID: 21730090
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.
Ntumngia FB; Barnes SJ; McHenry AM; George MT; Schloegel J; Adams JH
Clin Vaccine Immunol; 2014 Sep; 21(9):1215-23. PubMed ID: 24964808
[TBL] [Abstract][Full Text] [Related]
16. The Duffy binding protein as a key target for a Plasmodium vivax vaccine: lessons from the Brazilian Amazon.
de Sousa TN; Kano FS; de Brito CF; Carvalho LH
Mem Inst Oswaldo Cruz; 2014 Aug; 109(5):608-17. PubMed ID: 25185002
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for neutralization of Plasmodium vivax by naturally acquired human antibodies that target DBP.
Urusova D; Carias L; Huang Y; Nicolete VC; Popovici J; Roesch C; Salinas ND; Dechavanne S; Witkowski B; Ferreira MU; Adams JH; Gross ML; King CL; Tolia NH
Nat Microbiol; 2019 Sep; 4(9):1486-1496. PubMed ID: 31133752
[TBL] [Abstract][Full Text] [Related]
18. Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax duffy-binding protein.
Singh S; Pandey K; Chattopadhayay R; Yazdani SS; Lynn A; Bharadwaj A; Ranjan A; Chitnis C
J Biol Chem; 2001 May; 276(20):17111-6. PubMed ID: 11279211
[TBL] [Abstract][Full Text] [Related]
19. Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection.
King CL; Michon P; Shakri AR; Marcotty A; Stanisic D; Zimmerman PA; Cole-Tobian JL; Mueller I; Chitnis CE
Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8363-8. PubMed ID: 18523022
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II.
Ntumngia FB; Schloegel J; McHenry AM; Barnes SJ; George MT; Kennedy S; Adams JH
Vaccine; 2013 Sep; 31(40):4382-8. PubMed ID: 23916294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
